VICTORIA, BC, May 22, 2024
/PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or
the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage
biotechnology company leveraging its proprietary DiffuSphere™
technology to optimize drug delivery for applications with
significant unmet need, today announced that it will host a virtual
key opinion leader ("KOL") event on Wednesday, May 29, 2024, at 10:00 AM ET.
To register, please click here.
The event will feature Evan S.
Dellon, MD, MPH (University of North
Carolina School of Medicine) who will join Company
management to discuss the unmet medical need and current treatment
landscape for EoE. Dr. Dellon is Chairman of the Company's
Gastrointestinal Clinical Advisory Board.
The KOL event will focus on data from the Phase 1b/2a RESOLVE clinical trial and highlight
clinical development plans evaluating EP-104GI for the treatment of
EoE.
Utilizing the Company's proprietary DiffuSphere™ technology,
EP-104GI has shown the potential to target drug delivery to the
esophageal tissue and improve treatment outcomes for the EoE
patient population.
A live question-and-answer session will follow the formal
presentation.
About Evan S. Dellon, MD,
MPH
Evan S. Dellon, MD, MPH, is a
Professor of Medicine and Adjunct Professor of Epidemiology at the
University of North Carolina School of
Medicine in Chapel Hill. Dr. Dellon received his undergraduate
degree from Brown University and his
medical degree from Johns Hopkins School of
Medicine. He completed internship and residency in Internal
Medicine at Massachusetts General Hospital. He performed a clinical
and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of
Public Health degree in Epidemiology from the UNC School of Public
Health. Dr. Dellon is currently the Director of the UNC Center for
Esophageal Diseases and Swallowing (CEDAS) and has served as an
Associate Editor for Clinical Gastroenterology and Hepatology. Dr.
Dellon's main research interest is in the epidemiology,
pathogenesis, diagnosis, treatment, and outcomes of EoE and the
eosinophilic gastrointestinal diseases ("EGIDs"). The goal of his
research is to improve the lives of patients with EoE and EGIDs by
learning how to better diagnose, treat, and monitor these
conditions.
About Eosinophilic Esophagitis (EoE)
EoE is an inflammatory-mediated disease in which white blood
cells migrate into and become trapped in the esophagus, creating
pain and difficulty with swallowing food. According to market
research from Clearview, EoE
affects more than 450,000 people in the
United States and has been identified by the American
Gastroenterological Association as rapidly increasing in both
incidence and prevalence. Impacts from both symptoms and
interventions frequently lead to mental health issues, compounding
the disease burden of EoE for both the health care system and the
individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology designed to deliver targeted,
long-lasting activity with fewer side effects. DiffuSphere™, a
proprietary, polymer-based micro-sphere technology, is designed to
facilitate targeted drug delivery, with extended duration of
effect, and offers multiple, highly tuneable pharmacokinetic (PK)
profiles. This investigational technology can be engineered for use
with multiple active pharmaceutical ingredients and delivery
methods.
Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for
the treatment of pain due to osteoarthritis of the knee. The trial
met its primary endpoint and three of the four secondary endpoints.
Eupraxia has expanded the EP-104 platform into gastrointestinal
disease with the Phase 1b/2a RESOLVE
trial for treating eosinophilic esophagitis. Eupraxia is also
developing a pipeline of later- and earlier-stage long-acting
formulations. Potential pipeline indications include candidates for
other inflammatory joint indications and oncology, each designed to
improve on the activity and tolerability of currently approved
drugs. For further details about Eupraxia, please visit the
Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and
Information
This news release includes forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "suggests", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of
such words and phrases, or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Forward looking statements in this news release
include statements regarding the details of the Company's virtual
KOL event; the Company's product candidates, including expected
benefits to patients; the results gathered from studies and trials
of Eupraxia's product candidates; the potential for the Company's
technology to impact the drug delivery process; and potential
pipeline indications. Such statements and information are based on
the current expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties
related to the Company's limited operating history; the Company's
novel technology with uncertain market acceptance; if the Company
breaches any of the agreements under which it licenses rights to
its product candidates or technology from third parties, the
Company could lose license rights that are important to its
business; the Company's current license agreement may not provide
an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the
Company's future technology will require regulatory approval, which
is costly and the Company may not be able to obtain it; the Company
may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may
fail to demonstrate adequately the safety and efficacy of our
product candidates at any stage of clinical development; the
Company may be required to suspend or discontinue clinical trials
due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for
its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical
research services; the Company may not be able to successfully
execute its business strategy; the Company will require additional
financing, which may not be available; any therapeutics the Company
develops will be subject to extensive, lengthy and uncertain
regulatory requirements, which could adversely affect the Company's
ability to obtain regulatory approval in a timely manner, or at
all; the impact of health pandemics or epidemics on the Company's
operations; the Company's restatement of its consolidated financial
statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the
Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+
(sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
View original
content:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-host-virtual-kol-event-on-ep-104gi-clinical-development-program-for-eosinophilic-esophagitis-eoe-on-may-29-2024-302152284.html
SOURCE Eupraxia Pharmaceuticals Inc.